Welcome to our dedicated page for Enlivex Therapeutics Ltd. Ordinary Shares news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics Ltd. Ordinary Shares stock.
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage immunotherapy company focused on developing innovative allogeneic drugs to rebalance the immune system. The company's flagship product candidate, Allocetra™, is under development for multiple severe and critical conditions.
Allocetra™ is currently in a Phase IIB clinical trial targeting patients with severe sepsis, a life-threatening condition caused by the body's response to infection. Additionally, it is being investigated in a Phase II clinical trial for the treatment of COVID-19 patients with severe and critical conditions. The company is also exploring Allocetra™ in a Phase IIA trial for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplants (HSCT).
Enlivex is advancing Allocetra™ as a potential treatment for complications associated with bone marrow transplants, acute multiple organ failure, and as a combination therapy with various anti-cancer treatments to enhance efficacy. The immunotherapy works by reprogramming macrophages to their homeostatic state, thus rebalancing the immune system.
Recently, the Israeli Ministry of Health authorized a new trial for Allocetra™ targeting osteoarthritis, a chronic inflammatory condition affecting millions worldwide. This multi-country, double-blind, placebo-controlled Phase I/II trial aims to evaluate the safety and efficacy of Allocetra™ injections in knee osteoarthritis patients.
The company has shown promising results in its Phase II study of Allocetra™ in sepsis patients, demonstrating a favorable safety profile and potential effectiveness. With approvals from the Danish Medicines Agency and other international regulators, Enlivex is extending its clinical trials across multiple countries to further evaluate Allocetra™'s broad therapeutic potential.
Enlivex Therapeutics Ltd. has announced promising preclinical findings regarding the use of Allocetra™ in combination with anti-PD1 checkpoint inhibitors for treating ovarian cancer. Conducted in collaboration with Yale Cancer Center, the study showed a survival probability of up to 50% and an 83% increase in survival duration compared to untreated groups. This highlights Allocetra’s potential to enhance checkpoint inhibitor efficacy in difficult-to-treat cancers. The results will be presented at the ASCO Annual Meeting from June 3-7, 2022.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has been awarded a grant of approximately $1.2 million from the Israel Innovation Authority for its ongoing sepsis clinical trial in 2022. This brings the total non-dilutive funding from the IIA to about $7.8 million since the inception of their partnership. Enlivex is currently recruiting patients for its Phase IIb trial of AllocetraTM, aimed at treating organ dysfunction associated with sepsis. AllocetraTM is designed to reprogram macrophages, potentially addressing unmet medical needs in critical conditions.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) appointed Roger J. Pomerantz, M.D., as Vice Chairman of its Board of Directors. Dr. Pomerantz is a seasoned pharmaceutical expert with a history of leading significant business developments, including over 150 transactions at Merck & Co. and roles at Johnson & Johnson and Seres Therapeutics. He expressed excitement about Enlivex's Allocetra cell therapy, which aims to restore macrophage function in diseases like sepsis and solid tumors. The company anticipates a cash runway into Q3 2024, positioning it well for future growth.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the H.C. Wainwright Global Investment Conference from May 23–26, 2022. The company's presentation will be pre-recorded and accessible throughout the event. Enlivex is developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to combat diseases such as sepsis and solid tumors. Allocetra™ targets non-homeostatic macrophages that worsen these conditions, potentially offering a new immunotherapeutic approach for serious medical needs.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the Allogeneic Cell Therapies Summit 2022 and the 20th Biomed Israel Conference. Presentations include topics on their innovative therapy, Allocetra™, targeting solid tumors and cytokine storms linked to sepsis and COVID-19. Key details include a presentation on 'Next Generation Allogeneic Modality for Solid Tumors' on May 10, 2022, and two presentations at the Biomed Israel Conference on May 10 and 12. The focus is on the therapeutic potential of Allocetra™ in treating severe conditions.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced promising preclinical results for its cell therapy Allocetra™ combined with immune checkpoint inhibitors in treating mesothelioma. A study revealed up to 100% survival in mice receiving the combination treatment versus 0% survival in untreated mice. Allocetra™ alone achieved a 28.5% survival rate. This positions Allocetra™ as a potential innovative therapy for difficult-to-treat solid tumors, prompting plans for clinical trials in 2022 to evaluate its efficacy in patients with advanced-stage cancers.
Enlivex Therapeutics Ltd. announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163, securing intellectual property protection for treating sepsis with Allocetra™ until at least 2036. CEO Oren Hershkovitz emphasized that these patents strengthen their sepsis program, particularly for pneumonia, urinary, and biliary infections. The company is advancing its Phase II trial of Allocetra™, designed to reprogram macrophages and address life-threatening conditions. Enlivex aims to expand its patent portfolio globally.
Enlivex Therapeutics (Nasdaq: ENLV) announced the acceptance of an abstract for a poster presentation at the 2022 ASCO Annual Meeting, scheduled for June 3-7, 2022, at the McCormick Place in Chicago.
The poster, titled "In-vivo reprogramming macrophages and dendritic cells with Allocetra-OTS", covers successful antitumor therapy. The presentation will take place on June 5, 2022, between 8:00 AM and 11:00 AM CDT.
Allocetra™ aims to restore macrophage homeostasis, presenting a potential new immunotherapeutic approach for treating various diseases.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the completion of the frozen formulation of Allocetra™ in Q1 2022, twelve months ahead of schedule. This reformulation enhances shelf-life and manufacturing scalability, potentially lowering costs and increasing profitability. The company will integrate the frozen formulation into its ongoing Phase II sepsis trial, slightly delaying the trial's completion by 6-8 months but expediting eventual regulatory approval. Enlivex is deprioritizing its COVID-19 program to focus on sepsis and oncology, extending its cash runway to Q3 2024.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the issuance of Israeli Patent Number 255119 for 'Therapeutic Pooled Blood Apoptotic Cell Preparations.' This patent grants intellectual property protection in Israel until at least 2037, covering the use of pooled donor cells in their Allocetra product. CEO Oren Hershkovitz emphasized the importance of a strong patent portfolio in their corporate strategy. Enlivex is developing Allocetra as an off-the-shelf cell therapy aimed at reprogramming macrophages to treat severe diseases, addressing critical unmet medical needs.
FAQ
What is the current stock price of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)?
What is the market cap of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)?
What is Enlivex Therapeutics Ltd.?
What is Allocetra™?
What clinical trials are ongoing for Allocetra™?
What recent achievements has Enlivex made?
What is the significance of Allocetra™ in osteoarthritis treatment?
How does Allocetra™ work?
What are the benefits of Enlivex's therapy?
What is the company's financial condition?
What are the future plans for Allocetra™?
Where can I find more information about Enlivex?
